Participating Sites

Hospitals, universities, and other institutions participating with MCL.
Johns Hopkins Molecular and Cellular Characterization Laboratory (Prostate)

Together this work will yield highly relevant information that can be directly applied to the clinical management of localized prostate cancer. Specifically, it will yield an integrated signature that distinguishes localized – indolent tumors from localized tumors with lethal potential. Additionally we believe these signature will be critical in determining treatment strategies for individuals with prostate cancers of indeterminate kinetics.

MD Anderson Cancer Center Molecular and Cellular Characterization Laboratory (Pancreatic)

By integrating the amplitude and targets of the host immune response with quantitative physical features obtained using standard-of-care diagnostic imaging studies, we hope to develop reliable algorithms that can predict the risk of progression in pancreatic cysts using relatively non-invasive and portable approaches, and thereby address an unmet need of highest significance to public health.

UCLA-BU Stanford Molecular and Cellular Characterization Laboratory (Lung)

We hypothesize that the pathways underlying heterogeneity in screen-detected lung cancers will be revealed by analysis of molecular (whole exome and mRNA sequencing), microenvironment (immune and inflammatory mediators) and imaging characteristics (semantic and quantitative features) of screen- detected lesions.

Vanderbilt Molecular and Cellular Characterization Laboratory (Lung)

We will be able to build integrated models of ADC behavior, validate a new genomic molecular test on circulating DNA and propose prospective studies that would eventually offer a different intervention based on these predictions i.e. surgery, vs no surgery, adjuvant immuno- or chemotherapy vs no adjuvant therapy and therefore reduce overtreatment and ultimately increase the rate of cure and reduce healthcare cost.